Howard Burris, MD
Enriched profileAdvisor, Sarah Cannon Research Institute (retired as President, Clinical Operations and Chief Medical Officer in 2025; David R. Spigel, MD assumed President & CMO effective January 2026, alongside Melissa L. Johnson MD as Chief Scientific Officer and Erika P. Hamilton MD as Chief Development Officer) · Sarah Cannon Research Institute
Howard Burris is Advisor, Sarah Cannon Research Institute (retired as President, Clinical Operations and Chief Medical Officer in 2025; David R. Spigel, MD assumed President & CMO effective January 2026, alongside Melissa L. Johnson MD as Chief Scientific Officer and Erika P. Hamilton MD as Chief Development Officer) at Sarah Cannon Research Institute. OpenAlex indexes 1,155 publications with 72,593 citations (h-index 117); ClinicalTrials.gov lists 27 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Howard Burris as a Highly Cited Researcher (Clinical Medicine, 2015, 2019-2023; Cross-Field, 2018, 2024).
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Howard A. "Skip" Burris III, M.D., is Advisor, Sarah Cannon Research Institute (retired as President, Clinical Operations and Chief Medical Officer in 2025. The public record shows 1,155 publications with 72,593 citations (h-index 117), centered on Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research. It also documents an investigator role on 27 registered clinical trials, industry payments reported by 43 companies.
- Most recent indexed publication: 2026 · JCO oncology practice
- Top research focus: Cancer Treatment and Pharmacology
- 27 registered trials on ClinicalTrials.gov
- Open Payments reporting from 43 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 544.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sarahcannon.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 27 registered studies on ClinicalTrials.gov. The most recent:
- Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Sponsor: SCRI Development Innovations, LLC
Industry payments
Updated 27 Aug 2026
43 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- PFIZER INC.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
78.2%Corticosteroid78.2%Dexamethasone sodium phosphate100%Part B, office-administered≥22 patientsMetabolism & gastrointestinal
20.1%Serotonin-3 Receptor Antagonist20.1%Granisetron hydrochloride100%Part B, office-administered≥11 patientsCancer & immunology
1.7%Estrogen Agonist/Antagonist1.7%Tamoxifen Citrate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Clinical Research in Community Oncology: Advancing Cancer Care Through Localized Clinical Trials.
JCO oncology practice
Article2026 - The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.
Clinical cancer research
Clinical Trial2025 - ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.
Clinical cancer research
Article2025 - Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.
Clinical cancer research
Clinical Trial2025 - Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.
Clinical cancer research
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/howard-burris-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Howard-A-Burris-III-2038964496
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/burrisskip
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/hca_dr-howard-a-skip-burris-bringing-together-activity-6562810190629003264-3uHx
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/posts/sarah-cannon-research-institute_howard-a-skip-burris-iii-md-facp-fasco-activity-6348914594798456832-P_kE
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/posts/scri-oncology-partners_another-md-introduction-this-guy-needs-activity-7205929496271568897-uxHf
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- Hematology and Medical Oncology Fellowship
San Antonio Uniformed Services Health Education Consortium / Brooke Army Medical Center
1991verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Internal Medicine Residency
San Antonio Uniformed Services Health Education Consortium / Brooke Army Medical Center
1988verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- Undergraduate degree
United States Military Academy at West Point
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗ - Board Certified
American Board of Internal Medicine - Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Board Certified
American Board of Internal Medicine - Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Fellow
American College of Physicians (FACP)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →prnewswire.com ↗
Editorial & leadership roles
journal and society appointments- President
American Society of Clinical Oncology (ASCO), 2019-2020 term ('Unite and Conquer: Accelerating Progress Together')
2020verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dailynews.ascopubs.org ↗ - Chair
ASCO Board / Chair, Board of Conquer Cancer (the ASCO Foundation)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗ - Associate
Tennessee Oncology, PLLC
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bicycletherapeutics.com ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine201520192020202120222023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
- Cross-Field20182024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- 2014 Giants of Cancer Care Award
Drug Development category, from OncLive/Giants of Cancer Care program
2014verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗
- Board Member/Advisor
Bicycle Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bicycletherapeutics.com ↗
Media & interviews
press, podcasts and appearances- OncoDaily feature - 'Honoring President and Chief Medical Officer
Dr. Howard Skip Burris - Sarah Cannon Research Institute'
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - AJMC feature - 'As New Leaders Rise at SCRI
the Mission Remains: Bringing Clinical Trials Where Patients Live'
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dailynews.ascopubs.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
David Spigel, MD
Sarah Cannon Research Institute
Denise A. Yardley
Sarah Cannon Research Institute
Jesus Berdeja, MD
Sarah Cannon Research Institute
Erika Hamilton
Sarah Cannon Research Institute